摘要
目的 观察小剂量秋水仙碱联合依托考昔治疗急性痛风性关节炎的临床效果及安全性。方法 选择2015年12月~2016年5月在广州中医药大学附属海南省中医院就诊的60例急性痛风性关节炎患者,采用随机数字表法将其随机分为A、B、C三组,每组各20例。A组给予秋水仙碱片0.5 mg口服,每日3次;B组给予依托考昔片120 mg口服,每日1次;C组给予秋水仙碱片0.5 mg口服,每日3次,并加用依托考昔片60 mg口服,每日1次。疗程均为1周,观察综合疗效及安全性。结果 三组综合疗效比较,差异有统计学意义（P〈0.05）,C组疗效优于A组（P〈0.01）,与B组比较差异无统计学意义（P〉0.05）。三组治疗后血沉（ESR）及C反应蛋白（CRP）均较治疗前显著降低（P〈0.01）,但血尿酸水平变化差异无统计学意义（P〉0.05）。三组治疗后视觉模拟评分（VAS）均较治疗前明显降低（P〈0.01）,治疗后1-3 d,A组VAS评分均高于B组和C组（P〈0.01）,治疗后5、7 d,三组VAS评分比较差异无统计学意义（P〉0.05）。A组疼痛缓解时间较B组和C组长（P〈0.01）,B组不良反应发生率高于A组和C组（P〈0.05）。结论 小剂量秋水仙碱联合依托考昔能迅速改善急性痛风性关节炎患者的疼痛症状,且安全性较高。
Objective To observe the clinical effects and safety of small dose of Colchicine combined with Etoricoxib in the treatment of acute gouty arthritis. Methods Total 60 patients with acute gout arthritis treated in Hainan Hospital of Traditional Chinese Medicine Affiliated to Guangzhou University of Chinese Medicine from December 2015 to May 2016 were selected and randomly divided into three groups： group A, B and C by random number table method, with 20 cases in each group. The group A was given Colchicine 0.5 mg orally, 3 times a day; group B received Etoricoxib Tablets 120 mg orally, once a day; group C received Colchicine Tablets 0.5 mg orally, 3 times a day, and combined with Etoricoxib Tablets 60 mg orally, once a day. The course of treatment was 1 week, and the comprehensive efficacy and safety were observed. Results The comprehensive effect of the three groups had statistically significant differences （P 〈 0.05）, the curative effect of group C was better than that of group A （P 〈 0.01）, but the difference between group C and group B was not statistically significant （P 〉 0.05）. After treatment, the erythrocyte sedimentation rate （ESR） and C reactive protein （CRP） in the three groups were all lower than those before treatment （P 〈 0.01）, but the changes of blood uric acid had no significant difference （P 〉 0.05）. After treatment, the visual analogue scale （VAS） scores of the three groups were all significantly lower than those before treatment （P 〈 0.01）. After treatment for 1-3 days, the VAS scores of group A were higher than those of group B and group C （P 〈 0.01）, while the difference of VAS scores in the three groups were not significant after treatment for 5, 7 days （P 〉 0.05）. The time of pain relief in group A was significantly longer than those of group B and group C （P 〈 0.01）, and the incidence of adverse reactions in group B was higher than those of group A and group C （P 〈 0.05）. Conclusion Small dose of Colehicine combined with Etoricoxib can rapidly relieve the pain of patients with acute gouty arthritis, and the safety is high.
出处
《中国医药导报》
CAS
2016年第33期129-132,共4页
China Medical Herald
基金
国家临床重点专科(中医专业)建设项目(财社[2013]239号)
